Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.35
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London afternoon: Back to square one

Mon, 24th May 2010 13:42

Footsie has limped back into positive territory, helped by an about turn by the mining stocks.After spending the morning down in the dumps Rio Tinto is now the best performing mining stock as metal prices head northwards. Fellow mining stocks Xstrata and Anglo American join Rio on the rise but South African platinum miner Lonmin is still on the slide after its plans to get its Number One furnace back fully on line hit a snag that will add around 25-30 days to the commissioning process. The oil disaster in the Gulf of Mexico has cost BP about $760m (£525m) so far and the under-fire oil giant faces being "pushed out of the way" if its clean-up operation doesn't do better. So far 23,000 claims have been filed in relation to the MC252 oil well spill and 9,000 have already been paid. A week ago, it had cost the company about $625m.Peers Cairn Energy, Tullow Oil and Royal Dutch Shell are also among the worst performers.On the positive side, Prudential is wanted on reports that US firm AIG has drawn up plans to float its Asian arm again if the Pru's attempts to buy it collapse.British Airways has given up early gains. Cabin crew started their strike today despite last ditch attempts to get it averted.Travellers face massive disruption despite BA's attempt to fly as many planes as possible, although it had looked like industrial action could be avoided following a last-minute overture from the Unite union.Invensys grew full-year profit, though not by as much as analysts would have liked, but the firm still remains positive about the outlook based on its large order book and view of economic conditions. Profits fell by 25% at bid target Chloride last year, as recession hit its markets in Europe and the US. The power supplies group saw profits fall to £29.9m from £39.8m in the year to March, after a £5.9m one-of charge. Adjusted operating profits fell 4% to £44.7m. Sales rose by 3% to £336m.Pork products supplier Cranswick brought home the bacon last year, delivering a 26% surge in annual pre-tax profit. Revenues were up 22% to £740m. Net debt reduced by £11.9m to £54.7m. The company said it is encouraged by the positive start made in the current financial year. AG Barr, the Scottish soft drinks maker best known for its iconic Irn Bru concoction, said sales have continued frothing over in the new financial year.Recession has kept Albemarle & Bond's pawnbroker business performing strongly and it expects results for the 12 months to June 2010 to meet market expectations.Oil companies Europa and Aurelian are wanted after good progress on the Voitinel-1 well in the Brodina Block in Romania, in which they both have sizeable stakes.ValiRx, the biotech firm, has added Biovei's over the counter Chlamydia self-testing kit to its range of health screening products. Biomaterials and medical devices group Aortech has announced a non-exclusive technology licence and material supply agreement with a multi-billion dollar NYSE listed company to use the group's proprietary biostable co-polymer Elast-Eo as an integral part of a drug delivery platform for urological catheters.
More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.